Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1845528 | 0.85 | MAPT (0.50) | MAPTHTTNPC1JAK2RAB9A | |
| SCHEMBL11957625 | 0.82 | MAPT (0.67) | MAPTHTTNPC1JAK2RAB9A | |
| SCHEMBL1840030 | 0.82 | MAPT (0.67) | MAPTHTTNPC1JAK2RAB9A | |
| SCHEMBL1844573 | 0.77 | SOS1 (0.59) | PPARG | |
| SCHEMBL9874279 | 0.76 | PPARG (0.53) | PPARG | |
| SCHEMBL8396864 | 0.76 | PPARG (0.72) | RAB9APPARG | |
| SCHEMBL345 | 0.75 | AGTR1 (0.75) | — | |
| SCHEMBL9874062 | 0.74 | PPARG (0.54) | PPARG | |
| SCHEMBL9873184 | 0.73 | PPARG (0.51) | PPARG | |
| SCHEMBL9874652 | 0.73 | AGTR1 (0.71) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | claimed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2321281-A2 | ANTI INFLAMMATORY COMPOUNDS | Elder Pharmaceuticals Ltd (IN) | 2011-05-18 | — | — | EP | claimed |
| WO-2010029576-A2 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2010-03-18 | — | — | WO | claimed |
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | disclosed |
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | disclosed |
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | disclosed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | disclosed |
| EP-2321281-A2 | ANTI INFLAMMATORY COMPOUNDS | Elder Pharmaceuticals Ltd (IN) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010029576-A2 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010029576-A2 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | IL1B, LITAF, IL6 | MAPT 2758/4885HTT 4019/4885NPC1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.